Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00625443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
October 31, 2009
Enrollment
53 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura